This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Trulieve Cannabis (TRUL) Aktienübersicht
Trulieve Cannabis Corp. ist als Cannabis-Einzelhändler tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
TRUL Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Trulieve Cannabis Corp. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | CA$16.14 |
| 52-Wochen-Hoch | CA$18.50 |
| 52-Wochen-Tief | CA$4.45 |
| Beta | 1.86 |
| 1 Monat Veränderung | 46.06% |
| 3 Monate Veränderung | 83.83% |
| 1 Jahr Veränderung | 215.85% |
| 3 Jahre Veränderung | 202.81% |
| 5 Jahre Veränderung | -63.40% |
| Veränderung seit IPO | 61.72% |
Aktuelle Nachrichten und Updates
Recent updates
Narrativ-Update • May 30
TRUL: Schedule III Reclassification Pathway Will Drive Future Multiple Re Rating
Narrative Update on Trulieve Cannabis Analysts have raised their price target on Trulieve Cannabis by CA$8, reflecting updated assumptions for fair value, revenue growth, profit margins, and future P/E following recent sector research and regulatory commentary on cannabis rescheduling. Analyst Commentary Street research around Trulieve Cannabis has centered on how potential cannabis rescheduling could affect valuation, tax burdens, and long term earnings power.Narrativ-Update • Apr 23
TRUL: Schedule III Shift And Repriced P E Multiple Will Drive Upside
Analysts raised their price target for Trulieve Cannabis to CA$15.26 from CA$14.95, citing updated assumptions based on higher modeled revenue growth, stronger profit margins, and a more moderate future P/E multiple. Analyst Commentary Street research on the broader equity market has included several cautious revisions and lower price targets, which can help frame how bearish analysts might approach a stock like Trulieve Cannabis.
Narrativ-Update • Apr 08
TRUL: Higher Margin Profile And Rich Future P/E May Support Repricing
Analysts have lifted their fair value estimate for Trulieve Cannabis to CA$20.36 from CA$19.53, citing updated assumptions that reflect more conservative revenue growth, a higher profit margin profile, and a very large future P/E multiple that aligns with recent Street research patterns of recalibrating price targets while keeping core views intact. Analyst Commentary Street research across sectors shows a pattern of price target resets that keep long term theses largely intact, and this context helps frame how to read the updated fair value for Trulieve Cannabis.Narrativ-Update • Mar 24
TRUL: Schedule III Shift And Lower P E Multiple Will Drive Upside
Analysts have nudged their fair value price target for Trulieve Cannabis to CA$14.95, reflecting updated assumptions for slightly higher revenue growth, modestly improved profit margins, and a lower future P/E multiple in their models. Analyst Commentary While the latest fair value update suggests analysts see some improvement in Trulieve Cannabis' revenue and margin profile, there is still a clear undercurrent of caution in recent research across adjacent data and credit reporting names that can inform how you think about risk.Narrativ-Update • Mar 10
TRUL: Schedule III Shift And Higher P E Assumptions Will Drive Future Upside
Analysts have slightly raised their fair value estimate for Trulieve Cannabis to about CA$14.95 from CA$14.69, reflecting updated assumptions around slower revenue growth, tighter profit margins and a much higher future P/E multiple that mirrors recent Street work, where price targets have been adjusted while views on long term earnings power and business mix continue to evolve. Analyst Commentary Street research around information services and data providers has recently highlighted how quickly sentiment can shift when investors question earnings durability, pricing power or the impact of new technology.Narrativ-Update • Feb 24
TRUL: Rescheduling To Schedule III Will Shape Future Upside Potential
Analysts have trimmed their price target on Trulieve Cannabis by a small amount to reflect a slightly lower fair value estimate of CA$14.69. This incorporates updated assumptions that include modestly adjusted revenue growth, profit margin outlook and future P/E expectations.Analyseartikel • Feb 12
Some Confidence Is Lacking In Trulieve Cannabis Corp. (CSE:TRUL) As Shares Slide 30%
The Trulieve Cannabis Corp. ( CSE:TRUL ) share price has softened a substantial 30% over the previous 30 days, handing...Narrativ-Update • Feb 09
TRUL: Rescheduling To Schedule III Will Support Higher Future Earnings Multiples
Analysts have slightly raised their fair value estimate for Trulieve Cannabis to $19.53 from $19.06, citing updated assumptions around the discount rate, revenue growth, profit margins, and future P/E levels. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which would apply to companies such as Trulieve Cannabis that operate in the sector (Marijuana Herald).Narrativ-Update • Jan 25
TRUL: Future Rescheduling And Tax Relief Prospects Will Shape Upside Potential
Analysts have trimmed their fair value estimate for Trulieve Cannabis by about $0.12 to roughly $14.78, reflecting updated assumptions around slightly higher revenue growth, a wider profit margin profile, and a lower future P/E multiple. Analyst Commentary Some bearish analysts are using the latest fair value trim as a reminder that execution and growth expectations for Trulieve Cannabis still carry meaningful risk, even with a higher revenue and margin outlook built into the model.Narrativ-Update • Jan 11
TRUL: Retail Expansion And Rescheduling Progress Will Support Higher Future Earnings Multiples
Analysts have made a small upward adjustment to their Trulieve Cannabis fair value estimate, reflecting only modest tweaks to long term profit margin and future P/E assumptions rather than a wholesale shift in their outlook. Analyst Commentary Recent Street research around comparable business services and data providers offers some useful clues for how analysts may be thinking about Trulieve Cannabis valuation and execution, even though the coverage is focused on different companies.Narrativ-Update • Dec 27
TRUL: Retail Expansion Into New States Will Drive Future Earnings Multiples
Analysts nudged their price target on Trulieve Cannabis slightly higher, by about $0.16, as they factor in stronger multi year revenue growth, improving profit margins, and a more reasonable future earnings multiple, while still maintaining a similar discount rate framework. Analyst Commentary Recent commentary around Trulieve Cannabis reflects a more constructive, yet still measured, stance as analysts incorporate updated assumptions for growth, profitability, and regulatory visibility into their valuation work.Analyseartikel • Dec 22
Trulieve Cannabis Corp.'s (CSE:TRUL) Shares Climb 55% But Its Business Is Yet to Catch Up
Trulieve Cannabis Corp. ( CSE:TRUL ) shareholders would be excited to see that the share price has had a great month...Narrativ-Update • Dec 13
TRUL: Future Execution And Regulatory Shifts Will Shape Risk-Reward Balance
Analysts have lifted their price target on Trulieve Cannabis to approximately $14.90 from about $11.01, citing stronger expected revenue growth, improved profit margins, and a more reasonable future P/E multiple despite a slightly higher discount rate. Analyst Commentary Bearish analysts acknowledge Trulieve Cannabis's improved outlook but remain wary of execution and valuation risks in a still evolving regulatory and competitive landscape.Narrativ-Update • Nov 22
TRUL: Retail Expansion And New Markets Will Support Share Price Momentum
The analyst price target for Trulieve Cannabis has decreased slightly from $19.16 to $18.87. Analysts cite modest adjustments to profit margin expectations and valuation metrics as reasons for the change.Analyseartikel • Nov 08
Trulieve Cannabis Corp. (CSE:TRUL) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Shareholders might have noticed that Trulieve Cannabis Corp. ( CSE:TRUL ) filed its quarterly result this time last...Analyseartikel • Nov 07
Some Trulieve Cannabis Corp. (CSE:TRUL) Shareholders Look For Exit As Shares Take 29% Pounding
The Trulieve Cannabis Corp. ( CSE:TRUL ) share price has softened a substantial 29% over the previous 30 days, handing...Narrativ-Update • Nov 07
TRUL: Future Market Expansion Will Drive Share Price Momentum
Trulieve Cannabis’s analyst price target has been raised from $17.89 to $19.16. Analysts cite improved revenue growth projections and stable profit margins as key drivers for the upward revision.Analyseartikel • Oct 27
We Think Trulieve Cannabis (CSE:TRUL) Is Taking Some Risk With Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Aug 29
Trulieve Cannabis Corp.'s (CSE:TRUL) Shares Climb 97% But Its Business Is Yet to Catch Up
Trulieve Cannabis Corp. ( CSE:TRUL ) shares have continued their recent momentum with a 97% gain in the last month...Analyseartikel • Jul 11
Revenues Not Telling The Story For Trulieve Cannabis Corp. (CSE:TRUL) After Shares Rise 28%
Trulieve Cannabis Corp. ( CSE:TRUL ) shares have continued their recent momentum with a 28% gain in the last month...Analyseartikel • Jun 12
Does Trulieve Cannabis (CSE:TRUL) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Neues Narrativ • Mar 25
Adult-Use Cannabis Expansion In Florida And Pennsylvania Will Broaden Markets
Strategic retail expansion and new market entry in key states could significantly boost revenue and market share by tapping into adult-use markets.Analyseartikel • Jan 10
Here's Why Trulieve Cannabis (CSE:TRUL) Has A Meaningful Debt Burden
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analyseartikel • Dec 05
More Unpleasant Surprises Could Be In Store For Trulieve Cannabis Corp.'s (CSE:TRUL) Shares After Tumbling 56%
Trulieve Cannabis Corp. ( CSE:TRUL ) shares have had a horrible month, losing 56% after a relatively good period...Analyseartikel • Sep 04
Are Investors Undervaluing Trulieve Cannabis Corp. (CSE:TRUL) By 47%?
Key Insights The projected fair value for Trulieve Cannabis is CA$24.05 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Jun 15
Trulieve Cannabis Corp.'s (CSE:TRUL) 28% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Trulieve Cannabis Corp. ( CSE:TRUL ) shareholders won't be pleased to see that the share price has had a very rough...Analyseartikel • Jun 06
Trulieve Cannabis Corp.'s (CSE:TRUL) CEO Will Probably Struggle To See A Pay Rise This Year
Key Insights Trulieve Cannabis' Annual General Meeting to take place on 12th of June Salary of US$750.0k is part of CEO...Analyseartikel • May 01
Are Investors Undervaluing Trulieve Cannabis Corp. (CSE:TRUL) By 38%?
Key Insights The projected fair value for Trulieve Cannabis is CA$32.01 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Mar 31
Revenues Not Telling The Story For Trulieve Cannabis Corp. (CSE:TRUL) After Shares Rise 26%
Trulieve Cannabis Corp. ( CSE:TRUL ) shares have continued their recent momentum with a 26% gain in the last month...Analyseartikel • Feb 15
Is Trulieve Cannabis (CSE:TRUL) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jan 16
There's Reason For Concern Over Trulieve Cannabis Corp.'s (CSE:TRUL) Massive 29% Price Jump
The Trulieve Cannabis Corp. ( CSE:TRUL ) share price has done very well over the last month, posting an excellent gain...Aktionärsrenditen
| TRUL | CA Pharmaceuticals | CA Markt | |
|---|---|---|---|
| 7D | 16.9% | -3.3% | 1.1% |
| 1Y | 215.9% | 48.1% | 29.6% |
Rendite im Vergleich zur Industrie: TRUL übertraf die Branche Canadian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 48.1 erzielte.
Rendite vs. Markt: TRUL übertraf den Markt Canadian, der im vergangenen Jahr eine Rendite von 29.6 erzielte.
Preisvolatilität
| TRUL volatility | |
|---|---|
| TRUL Average Weekly Movement | 15.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in CA Market | 16.8% |
| 10% least volatile stocks in CA Market | 3.7% |
Stabiler Aktienkurs: Der Aktienkurs von TRUL war in den letzten 3 Monaten im Vergleich zum Canadian -Markt volatil.
Volatilität im Zeitverlauf: TRULDie wöchentliche Volatilität (15%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der Canadian Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1940 | 5,000 | Kim Rivers | www.trulieve.com |
Trulieve Cannabis Corp. ist als Cannabis-Einzelhändler tätig. Das Unternehmen kultiviert, verarbeitet und produziert Cannabisprodukte und vertreibt seine Produkte an seine Apotheken sowie durch Hauslieferungen. Es verkauft Blumen, Esswaren, Konzentrate und Zubehör unter den Marken Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers und Roll One.
Trulieve Cannabis Corp.'s Grundlagenzusammenfassung
| TRUL grundlegende Statistiken | |
|---|---|
| Marktanteil | CA$3.10b |
| Gewinn(TTM) | -CA$106.04m |
| Umsatz(TTM) | CA$1.63b |
1.9x
Kurs-Umsatz-Verhältnis-29.3x
Kurs-Gewinn-Verhältnis Ist TRUL zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| TRUL Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$1.17b |
| Kosten der Einnahmen | US$472.15m |
| Bruttogewinn | US$698.03m |
| Sonstige Ausgaben | US$774.07m |
| Gewinn | -US$76.04m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.40 |
| Bruttomarge | 59.65% |
| Nettogewinnspanne | -6.50% |
| Schulden/Eigenkapital-Verhältnis | 25.3% |
Wie hat sich TRUL auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/11 12:51 |
| Aktienkurs zum Tagesende | 2026/06/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Trulieve Cannabis Corp. wird von 15 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Matt Bottomley | Canaccord Genuity |